ANDA 76323, held by Hikma Pharmaceuticals. Esmolol Hydrochloride.
As of Nov 21, 2026, ANDA 76323 (Esmolol Hydrochloride), held by Hikma Pharmaceuticals, was first approved by FDA on Aug 10, 2004, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 10, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Esmolol Hydrochloride10MG/ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Apr 11, 2008 | Supplement 4Labeling | Approved | None posted |
| Aug 10, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters